Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||anti-thymocyte globulin + Ibritumomab tiuxetan + Rituximab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Ibritumomab tiuxetan||Zevalin||IDEC Y2B8||CD20 Antibody 10||Zevalin (britumomab tiuxetan) is Yttrium-90 combined with the anti-CD20 antibody, rituximab, which may deliver radiation to tumor cells (PMID: 27497027). Zevalin (britumomab tiuxetan) is FDA approved for use in patients with low-grade or follicular B-cell non-Hodgkin's lymphoma (FDA.gov).|
|Rituximab||Rituxan||IDEC-C2B8|MabThera||CD20 Antibody 10||Rituxan (rituximab) is a chimeric mononclonal antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent and antibody-dependent cytotoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use as monotherapy or in combination with chemotherapy in CD20-positive B-cell non-Hodgkin lymphoma, and in combination with fludarabine and cyclophosphamide in CD20-positive chronic lymphocytic leukemia (FDA.gov).|
|anti-thymocyte globulin||Thymoglobulin||lymphocyte immune globulin|ATGAM||Thymoglobulin (anti-thymocyte globulin) is an immunoglobulin that binds to and destroys T-lymphocytes, which may aid in reduction of graft-vs-host disease when administered with stem cell transplantation (PMID: 32624582).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT01811368||Phase II||anti-thymocyte globulin + Ibritumomab tiuxetan + Rituximab Cyclosporine + Mycophenolate mofetil||Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma||Recruiting|